Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures
- PMID: 25344422
- DOI: 10.1007/s10620-014-3397-7
Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures
Abstract
Background: The role of M2-PK (pyruvate kinase) in bile has not been studied in comparison with brushings and carbohydrate antigen (CA) 19-9 in the diagnosis of malignant biliary strictures.
Aim: To compare the diagnostic accuracy of biliary M2-PK with cytology and serum CA 19-9 METHODS: In this prospective cross-sectional study, bile was aspirated in 74 patients (discovery and validation cohort) undergoing endoscopic retrograde cholangiopancreatography. Levels of M2-PK were measured in bile and compared to brushings for cytology and CA 19-9.
Results: In the discovery cohort, the median bile M2-PK levels were significantly elevated in patients with malignant biliary strictures [187.9 U/l (interquartile range (IQR) 3.5, 3626.8)] compared to those with benign biliary conditions and primary sclerosing cholangitis [0 U/l (IQR 0, 15)] (P = 0.007). A M2-PK cutoff value of 109.1 U/l distinguished malignant from benign conditions with a sensitivity and specificity of 52.9 and 94.1 %, respectively, and area under curve (AUC) of 0.77. The sensitivity of CA 19-9 and brushings in diagnosing cancer was 52.9 % and 11.1 % and specificity 94.1 and 100 %, respectively. The presence of elevated M2-PK >109.1 U/l or CA 19-9 >33 U/ml or positive brushing was 88.2 % sensitive and 88.2 % specific, AUC of 0.89 in the diagnosis of malignancy. The diagnostic accuracy was confirmed in the validation cohort.
Conclusions: As a stand-alone factor, none of the markers were able to distinguish benign from malignant biliary strictures with a high sensitivity. However, a combination was highly sensitive in diagnosing malignant biliary strictures.
Similar articles
-
Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures.Gut. 2020 Jan;69(1):52-61. doi: 10.1136/gutjnl-2018-317817. Epub 2019 Apr 10. Gut. 2020. PMID: 30971436 Free PMC article.
-
Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.Endoscopy. 2002 Nov;34(11):909-16. doi: 10.1055/s-2002-35298. Endoscopy. 2002. PMID: 12430077
-
Effectiveness for Diagnosis of Malignancy of Bile Pyruvate Kinase M2 in Patients with Indeterminate Biliary Stricture.Surg Laparosc Endosc Percutan Tech. 2023 Apr 1;33(2):147-151. doi: 10.1097/SLE.0000000000001158. Surg Laparosc Endosc Percutan Tech. 2023. PMID: 36977323
-
Practical Management of Indeterminate Biliary Strictures.Gastrointest Endosc Clin N Am. 2019 Apr;29(2):205-214. doi: 10.1016/j.giec.2018.12.003. Epub 2019 Feb 2. Gastrointest Endosc Clin N Am. 2019. PMID: 30846149 Review.
-
Adult bile duct strictures: role of MR imaging and MR cholangiopancreatography in characterization.Radiographics. 2014 May-Jun;34(3):565-86. doi: 10.1148/rg.343125211. Radiographics. 2014. PMID: 24819781 Review.
Cited by
-
Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.Front Immunol. 2022 Oct 28;13:1049812. doi: 10.3389/fimmu.2022.1049812. eCollection 2022. Front Immunol. 2022. PMID: 36389727 Free PMC article. Review.
-
The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas.J Clin Diagn Res. 2016 Mar;10(3):PC06-9. doi: 10.7860/JCDR/2016/17106.7398. Epub 2016 Mar 1. J Clin Diagn Res. 2016. PMID: 27134925 Free PMC article.
-
Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.Am J Trop Med Hyg. 2018 Jun;98(6):1788-1797. doi: 10.4269/ajtmh.17-0879. Epub 2018 Apr 5. Am J Trop Med Hyg. 2018. PMID: 29637880 Free PMC article.
-
BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma.Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971676. doi: 10.1177/1533033820971676. Technol Cancer Res Treat. 2020. PMID: 33234031 Free PMC article.
-
Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.Cancers (Basel). 2022 Aug 13;14(16):3921. doi: 10.3390/cancers14163921. Cancers (Basel). 2022. PMID: 36010914 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials